Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMETEK, Inc. (AME) vs Boston Scientific Corporation (BSX) Price & Performance

AMETEK, Inc.Trade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

AMETEK, Inc. vs Boston Scientific Corporation — how do they compare? AMETEK, Inc. trades at $257.95 (market cap $58.76B), while Boston Scientific Corporation trades at $51.45 (market cap $74.19B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and AMETEK, Inc. pays a 0.53% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

AMEBSX
Market Cap
$58.76B$74.19B
Sector
IndustrialsHealth
52-Week High
$256.30$108.14
52-Week Low
$179.28$42.63
Enterprise Value
$60.30B$86.27B
Dividend Yield
0.53%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMETEK, Inc.

AME trades at $252.88, down 0.31% on the day, with a bullish technical signal from moving averages and strong support near $252. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance, reflecting robust demand. Revenue grew to $7.4B in 2025, with a net margin of 20.04%, while valuation ratios like P/E of 37.47 suggest a premium. Recent news highlights momentum and inclusion in high-growth themes like 3D printing.

Outlook remains positive given earnings beats and analyst consensus, but risks include elevated valuation and macroeconomic sensitivity. The stock offers growth potential with a $281.86 price target, though investors should monitor execution against guidance and industry competition.

Boston Scientific Corporation

BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.

Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AMETEK, Inc.

Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.

Read more on AME

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX